Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
ABSTRACTBackground and objectives: Multiple reforms aimed at improving the Chinese population’s health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anti...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20016689.2023.2218633 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045643879350272 |
|---|---|
| author | Bérengère Macabeo Liam Wilson Jianwei Xuan Ruichen Guo Petar Atanasov Linda Zheng Clement François Philippe Laramée |
| author_facet | Bérengère Macabeo Liam Wilson Jianwei Xuan Ruichen Guo Petar Atanasov Linda Zheng Clement François Philippe Laramée |
| author_sort | Bérengère Macabeo |
| collection | DOAJ |
| description | ABSTRACTBackground and objectives: Multiple reforms aimed at improving the Chinese population’s health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anticipate future trends.Methods: Targeted reviews of published literature and statistics on the Chinese healthcare system, medical insurance and reimbursement processes were conducted, as well as interviews with five Chinese experts involved in the reimbursement of innovative drugs.Results: Drug reimbursement in China is becoming increasingly centralized due to the removal of provincial pathways, the establishment of the National Healthcare Security Administration and the implementation of the National Reimbursement Drug List (NRDL), which is now the main route for drug reimbursement in China. There is also an increasing number of other channels via which patients may access innovative treatments, including various types of commercial insurance and special access. Health technology assessment (HTA) and health economic evidence are becoming pivotal elements of the NRDL decision-making process. Alongside the optimization of HTA decision making, innovative risk-sharing agreements are anticipated to be increasingly leveraged in the future to optimize access to highly specialized technologies and encourage innovation while safeguarding limited healthcare funds.Conclusions: Drug public reimbursement in China continues to align more closely with approaches widely used in Europe in terms of HTA, health economics and pricing. Centralization of decision-making processes for public reimbursement of innovative drugs allows consistency in assessment and access, which optimizes the improvement of the Chinese population’s health. |
| format | Article |
| id | doaj-art-eb9bcc37434f4471b8a74f335ac2dc42 |
| institution | DOAJ |
| issn | 2001-6689 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-eb9bcc37434f4471b8a74f335ac2dc422025-08-20T02:54:39ZengMDPI AGJournal of Market Access & Health Policy2001-66892023-12-0111110.1080/20016689.2023.2218633Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursementBérengère Macabeo0Liam Wilson1Jianwei Xuan2Ruichen Guo3Petar Atanasov4Linda Zheng5Clement François6Philippe Laramée7Aix-Marseille Université, Marseille, FranceHealth Economics and Market Access, Amaris Consulting, Shanghai, ChinaHealth Economic Research Institute, Sun Yat-Sen University, Guangzhou, ChinaInstitute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, ChinaHealth Economics and Market Access, Amaris Consulting, Barcelona, SpainPierre Fabre Group, Shanghai, ChinaAix-Marseille Université, Marseille, FranceAix-Marseille Université, Marseille, FranceABSTRACTBackground and objectives: Multiple reforms aimed at improving the Chinese population’s health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anticipate future trends.Methods: Targeted reviews of published literature and statistics on the Chinese healthcare system, medical insurance and reimbursement processes were conducted, as well as interviews with five Chinese experts involved in the reimbursement of innovative drugs.Results: Drug reimbursement in China is becoming increasingly centralized due to the removal of provincial pathways, the establishment of the National Healthcare Security Administration and the implementation of the National Reimbursement Drug List (NRDL), which is now the main route for drug reimbursement in China. There is also an increasing number of other channels via which patients may access innovative treatments, including various types of commercial insurance and special access. Health technology assessment (HTA) and health economic evidence are becoming pivotal elements of the NRDL decision-making process. Alongside the optimization of HTA decision making, innovative risk-sharing agreements are anticipated to be increasingly leveraged in the future to optimize access to highly specialized technologies and encourage innovation while safeguarding limited healthcare funds.Conclusions: Drug public reimbursement in China continues to align more closely with approaches widely used in Europe in terms of HTA, health economics and pricing. Centralization of decision-making processes for public reimbursement of innovative drugs allows consistency in assessment and access, which optimizes the improvement of the Chinese population’s health.https://www.tandfonline.com/doi/10.1080/20016689.2023.2218633National Reimbursement Drug Listinnovative drug accesspricingreimbursementdecision makinghealth technology assessment |
| spellingShingle | Bérengère Macabeo Liam Wilson Jianwei Xuan Ruichen Guo Petar Atanasov Linda Zheng Clement François Philippe Laramée Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement Journal of Market Access & Health Policy National Reimbursement Drug List innovative drug access pricing reimbursement decision making health technology assessment |
| title | Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement |
| title_full | Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement |
| title_fullStr | Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement |
| title_full_unstemmed | Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement |
| title_short | Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement |
| title_sort | access to innovative drugs and the national reimbursement drug list in china changing dynamics and future trends in pricing and reimbursement |
| topic | National Reimbursement Drug List innovative drug access pricing reimbursement decision making health technology assessment |
| url | https://www.tandfonline.com/doi/10.1080/20016689.2023.2218633 |
| work_keys_str_mv | AT berengeremacabeo accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT liamwilson accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT jianweixuan accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT ruichenguo accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT petaratanasov accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT lindazheng accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT clementfrancois accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement AT philippelaramee accesstoinnovativedrugsandthenationalreimbursementdruglistinchinachangingdynamicsandfuturetrendsinpricingandreimbursement |